A Spanish healthcare research institute has developed silica particles for nucleic acid encapsulation, which are able to transport and transfer gen therapies and proteins into cells. In addition, they are stable at room temperature, versatile and cost-effective. The Institute is looking for companies interested in the use of this patent protected silica particles to cooperate in the framework of a commercial agreement with technical assistance or a research and development agreement.
The Spanish healthcare research institute promotes and develops research and innovation in the bio-health environment, with the aim of seeking solutions to health problems and contributing to scientific, educational, social and economic development. The technology developer is a consolidated group with large experience in molecular biology. They have worked in collaboration with another investigation centre. The design of vectors that can effectively encapsulate, protect and target nucleic acids to specific cells safely and precisely is a major challenge in science today. The silica particles developed overcome the problems of the vectors used so far and present great stability, resistance, transfection efficiency, and design versatility. These nanoparticles can be of interest for the treatment of pathologies ranging from genetic disorders and cancers to infectious and parasite-related diseases caused by pathogens that are not targetable through conventional means. These particles can be conjugated with a variety of other components such as fluorescent molecules, magnetics nanoparticles or ligands, in accordance with the expected use of the particle. https://www.sciencedirect.com/science/article/pii/S2590049823000176 The research institute would like to talk to companies interested in the use of this patent protected silica particles (P202130804) to cooperate in the framework of a commercial agreement with technical assistance or a research and development agreement.
Advantages and innovations
Among the advantages of this technology are: - Can be produced and tested industrially. - Excellent storability. - Can be efficiently functionalized to achieve fully customizable, cell-targeted systems. - Have no DNA type/size limitations. - Do not produce cytotoxicity. - Makes it possible to control the expression of different genes in a sequential and chronologically programmable manner. - Cost efficient.
Technical Specification or Expertise Sought
- Type of partner sought: Pharmaceutical industries or veterinary industries. - Specific area of activity of the partner: Development and commercialization of gene therapies, vaccines, protein/enzymatic replacement therapy
Contact / source: NEXT EEN Widgets (europa.eu)
IF YOU ARE INTERESTED IN KNOWING MORE
ABOUT THIS PROJECT PLEASE
REGISTER AS FREE MEMBER OR LOGIN IF ALREADY REGISTERED
Contact us for more informations